Scinovex
article Open AccessTop 1% cited

Executive Summary

CHEST Journal · 2012 · Vol. 141(2) · pp. 7S–47S
Gordon GuyattElie A. AklMark CrowtherDavid D. GuttermanHolger J. Schuünemann

MeSH terms

Fibrinolytic AgentsHumansSocieties, MedicalThrombosisUnited StatesPractice Guidelines as TopicEvidence-Based Medicine

Funding

  • Bristol-Myers Squibb
  • GlaxoSmithKline
  • Sanofi
  • CSL Behring
  • Bayer HealthCare
  • LEO Pharma
  • National Institutes of Health
  • National Heart, Lung, and Blood Institute
Citations
1,539
FWCI
119.90
field-weighted impact
References
15
Percentile
100%
vs. same field & year
Citations per year
References
Antithrombotic Therapy in Neonates and Children
CHEST Journal · 2012 · 1,449 citations
Prevention of VTE in Nonsurgical Patients
CHEST Journal · 2012 · 2,664 citations
Antithrombotic Therapy for Atrial Fibrillation
CHEST Journal · 2012 · 918 citations
Antithrombotic Therapy for VTE Disease
CHEST Journal · 2012 · 6,117 citations
Treatment and Prevention of Heparin-Induced Thrombocytopenia
CHEST Journal · 2012 · 1,002 citations
Prevention of VTE in Nonorthopedic Surgical Patients
CHEST Journal · 2012 · 2,091 citations
VTE, Thrombophilia, Antithrombotic Therapy, and Pregnancy
CHEST Journal · 2012 · 1,488 citations
Perioperative Management of Antithrombotic Therapy
CHEST Journal · 2012 · 1,629 citations
Citation Network

How this paper connects to the literature. Drag to explore, click any node to open that paper.